Inventor · disambiguated record
Roy Lobb
Also filed as: GOELZ SUSAN E · LOBB ROY · LOBB ROY R
29 granted patents·21 pending applications·836 citations·filing 1989–2021
97Inventor score
Files withALETA BIOTHERAPEUTICS INC12BIOGEN INC9BIOGEN IDEC INC7US HEALTH3BIOGEN IDEC MA INC A MASSACHUS2
Top patents by PatentIndex Score
50 records- 0198US7829092B2Recombinant anti-VLA4 antibody moleculesBIOGEN IDEC INC·Filed 2008·Granted Nov 9, 2010·60 cites·28 claims
- 0297US6602503B1Recombinant anti-VLA-4 antibody moleculesBIOGEN INC·Filed 1995·Granted Aug 5, 2003·183 cites·146 claims
- 0395US8226950B2Recombinant anti-VLA4 antibody moleculesLOBB ROY R·Filed 2010·Granted Jul 24, 2012·49 cites·1 claims
- 0494US10508143B1Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2016·Granted Dec 17, 2019·7 cites·4 claims
- 0594US5272263ADNA sequences encoding vascular cell adhesion molecules (VCAMS)BIOGEN INC·Filed 1989·Granted Dec 21, 1993·72 cites·9 claims
- 0693US5932214ATreatment for inflammatory bowel disease with VLA-4 blockersBIOGEN INC·Filed 1997·Granted Aug 3, 1999·90 cites·15 claims
- 0790US10066023B2Compositions and methods for tumor transductionALETA BIOTHERAPEUTICS INC·Filed 2016·Granted Sep 4, 2018·3 cites·16 claims
- 0889US7482003B2Treatment for asthma with α4-specific antibodiesBIOGEN IDEC INC·Filed 2006·Granted Jan 27, 2009·9 cites·11 claims
- 0988US10669349B2Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2017·Granted Jun 2, 2020·2 cites·12 claims
- 1088US5871734ATreatment for asthma with VLA-4 blocking agentsBIOGEN INC·Filed 1997·Granted Feb 16, 1999·58 cites·22 claims
- 1188US5367056AEndothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)BIOGEN INC·Filed 1993·Granted Nov 22, 1994·50 cites·6 claims
- 1287US7157086B2Treatment for inflammatory bowel disease with α4-specific antibodiesBIOGEN IDEC INC·Filed 2003·Granted Jan 2, 2007·18 cites·11 claims
- 1387US6482409B1Treatment for inflammatory bowel disease with a vcam-1/1gG fusion proteinBIOGEN INC·Filed 1998·Granted Nov 19, 2002·48 cites·11 claims
- 1486US8084031B2Method for the treatment of inflammatory disordersGOTWALS PHILIP·Filed 2008·Granted Dec 27, 2011·7 cites·15 claims
- 1586US7462353B2Method for the treatment of inflammatory disordersBIOGEN IDEC INC·Filed 2005·Granted Dec 9, 2008·12 cites·13 claims
- 1686US6955810B2Method for the treatment of inflammatory disordersBIOGEN IDEC INC·Filed 2001·Granted Oct 18, 2005·20 cites·7 claims
- 1786US6252043B1Vascular cell adhesion molecule (VCAM) polypeptidesBIOGEN INC·Filed 1994·Granted Jun 26, 2001·47 cites·5 claims
- 1885US10072094B2Compositions and methods for tumor transductionALETA BIOTHERAPEUTICS INC·Filed 2017·Granted Sep 11, 2018·2 cites·28 claims
- 1984US11059904B2Compositions and methods for tumor transductionALETA BIOTHERAPEUTICS INC·Filed 2018·Granted Jul 13, 2021·1 cites·29 claims
- 2084US8557240B2Method for the treatment of inflammatory disordersGOTWALS PHILIP·Filed 2011·Granted Oct 15, 2013·6 cites·20 claims
- 2184US5217870AMonoclonal antibodies against CDXBIOGEN INC·Filed 1989·Granted Jun 8, 1993·48 cites·3 claims
- 2282US6307025B1VCAM fusion proteins and DNA coding thereforBIOGEN INC·Filed 1995·Granted Oct 23, 2001·35 cites·7 claims
- 2378US9556426B2Protein kinase conjugates and inhibitorsSINGH JUSWINDER·Filed 2010·Granted Jan 31, 2017·3 cites·48 claims
- 2475US7176184B2Treatment for inflammatory bowel disease with a fibronectin polypeptideBIOGEN IDEC INC·Filed 2002·Granted Feb 13, 2007·5 cites·9 claims
- 2574US10662195B2Protein kinase conjugates and inhibitorsCELGENE AVILOMICS RES INC·Filed 2016·Granted May 26, 2020·1 cites·1 claims
- 2669US11807691B2Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2020·Granted Nov 7, 2023·0 cites·15 claims
- 2767US2022313720A1Targeted cancer therapyUS HEALTH·Filed 2021·Application pending·0 cites
- 2861US11207339B2Targeted cancer therapyUS HEALTH·Filed 2016·Granted Dec 28, 2021·0 cites·17 claims
- 2961US2014234299A1Therapies for chronic renal failure using one or more integrin antagonistsIMPERIAL COLLEGE·Filed 2014·Application pending·0 cites
- 3060US2007253902A1Treatment for inflammatory bowel diseaseBIOGEN IDEC MA INC A MASSACHUS·Filed 2006·Application pending·0 cites
- 3159US9902774B2Method for the treatment of inflammatory disordersBIOGEN MA INC·Filed 2013·Granted Feb 27, 2018·0 cites·44 claims
- 3258US2007149769A1Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)BIOGEN INC A MASSACHUSETTS COR·Filed 2006·Application pending·0 cites
- 3357US2003007969A1Therapies for chronic renal failure using one or more integrin antagonistsFiled 2002·Application pending·0 cites
- 3455US2023220095A1Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3555US2022112292A1Single domain antibodies against cll-1ALETA BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3654US2003153731A1Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)Filed 2002·Application pending·0 cites
- 3754US2011305686A1Therapies for chronic renal failure using one or more integrin antagonistsLOBB ROY·Filed 2011·Application pending·0 cites
- 3853US2006115473A1Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonistsBIOGEN IDEC MA INC A MASSACHUS·Filed 2005·Application pending·0 cites
- 3953US2013011390A1Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonistsBIOGEN IDEC INC·Filed 2012·Application pending·0 cites
- 4051US2006013808A1Treatment for asthmaBIOGEN INC A MASSACHUSETTS COR·Filed 2005·Application pending·0 cites
- 4150US2022387487A1Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4250US2014127195A1Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonistsRELTON JANE K·Filed 2014·Application pending·0 cites
- 4348US11891426B2CD19 variantsALETA BIOTHERAPEUTICS INC·Filed 2018·Granted Feb 6, 2024·0 cites·10 claims
- 4448US2020306375A1Compositions and methods for tumor transductionALETA BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4548US2021130494A1Compositions and methods for treatment of cancerALETA BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4647US2003027744A1Use of a CD40:CD154 binding interruptor to treat immunological complications of the eyeFiled 2002·Application pending·0 cites
- 4746US2019144503A1Methods for the identification of bifunctional compoundsUNIV MINNESOTA·Filed 2017·Application pending·0 cites
- 4842US2007025965A1Therapies for renal failure using interferon-betaLOBB ROY R·Filed 2003·Application pending·0 cites
- 4941US2018311374A1Targeted cancer therapyUS HEALTH·Filed 2016·Application pending·0 cites
- 5040US2002197233A1Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonistsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Roy Lobb files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →